|
|
|
For each new drug produced, pharmaceutical companies require hundreds of researchers, scientists, and clinical trial organizations to work together efficiently. Delays in time-to-market erode revenues and profits.Any solution that helped monitor and control this company’s IP must not impede the productivity of the users. The scientific applications used by R&D professionals were an important repository for IP. The data resulting from these included specific formulae that may be required in other documents and data. The company required that information to remain confidential, even when moved between documents, inside or outside the original application environment. Finally, the organization relied heavily on third party individuals and organizations, with whom it shared critical data. Independent scientists would work on projects, and independent organizations were required to conduct clinical trials. IP shared with these partners must be protected. Complete the form to download this resource in full. |
